Resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) increases with the wider use of this class of antiretroviral therapy. The association between adherence and resistance to NNRTI-based regimens is poorly understood. Predictors of virologic failure and resistance according to a baseline evaluation of nonadherence risk factors were determined in a cohort of 71 human immunodeficiency virus (HIV)-infected patients with early virologic response who received an NNRTI-based regimen. During the median follow-up of 29 months, 20 (28%) of 71 patients experienced virologic failure with an NNRTI-based regimen. Virologic failure was associated with repeated drug holidays (у48 h of unplanned drug cessation), depression, younger age, and low adherence to therapy during baseline evaluation. Moreover, repeated drug holidays was the only risk factor for developing a major mutation conferring cross-resistance to the NNRTI class (hazard ratio, 22.5; 95% confidence interval, 2.8-180.3;
) in the United States [4] , and similar findings have .01 been reported in Europe [5] . In contrast, primary resistance to PIs in newly infected patients remained stable [4] . The relationship between low adherence to therapy and virologic failure has been clearly established in PI-containing regimens [6] [7] [8] . Very low levels of adherence to PI therapy, however, do not increase the risk of conferring protease mutations necessary to reduce susceptibility to these drugs, as compared with higher levels of adherence [9] [10] [11] . For example, adherence over 6 months was positively associated with new PI drug mutations ( ) in 44 people receiving a PI [11] . P ! .0001 In contrast, another study [12] found that 70%-89% adherence to therapy increased the risk of virologic failure with resistance mutations, as compared with perfect adherence; however, 40% of the patients received NNRTI-based regimens, and 41% received PIbased regimens. The level of nonadherence associated with the greatest risk of developing resistance is probably affected by whether the regimen is based on NNRTIs or PIs and by the way nonadherence is assessed.
To investigate this issue in patients with virus loads controlled early in the course of NNRTI therapy, we prospectively evaluated the time to virologic failure and resistance according to a cross-sectional structured evaluation of patient characteristics, including previous adherence to antiretroviral therapy.
PATIENTS AND METHODS
Study population and data collection. The study was conducted in 2 infectious diseases outpatient clinics in France (Bichat-Claude Bernard University Hospital, Paris, and Côte de Nacre University Hospital, Caen). We enrolled all consecutive HIV-infected patients who had been identified in the previous year or before and whose virus loads had been controlled with the same HAART, which contained nevirapine or efavirenz. The NNRTIs had been introduced for the first time 3-6 months before we initiated the study. Demographic, epidemiologic, clinical, biological, and treatment information were retrospectively collected from the medical files. Standardized psychosociological and baseline adherence-related data were collected by interview from August 1999 through August 2000. We assessed previous nonadherence to therapy by the use of a 4-item scale questionnaire [13, 14] and the self-reported number of drug holidays [14] (defined as stopping the regimen entirely for у48 h) from the first initiation of any antiretroviral treatment. These tools have been prospectively validated to assess adherence to antiretroviral treatment against virus load and electronic monitoring in HIV infection, with a sensitivity of 72% and a specificity of 91% to detect adherence 190% [14] . Depression was evaluated according to the 7-item Hospital Anxiety and Depression Scale validated for ambulatory and hospitalized HIV-infected patients [15] .
Subsequent virus load levels were prospectively measured by the assay routinely available in the center, with lower limits of detection of 50 copies/mL. A virus load of 1400 copies/mL, confirmed by a successive second virus load of 1400 copies/ mL, was considered to represent virologic failure. Genotypic resistance testing was performed in case of virologic failure. We defined NNRTI resistance as the presence of у1 mutation at the codon L100I, K101E, K103N, Y181C/I, Y188C/L, and G190A/C/E/Q/S/T/V. In addition, V106A for nevirapine and P225H for efavirenz were also considered as NNRTI resistance.
Statistical analysis. On the basis of reported risk factors for virologic failure in patients receiving a PI-based regimen, we compared the rates of subsequent virological failure according to the following baseline factors: nonadherence behaviors, number of drug holidays, depression, social support, medication knowledge, risk factor for HIV, age, sex, CD4 cell count, NNRTI prescribed, and nucleoside reverse transcriptase inhibitor prescribed. Because efavirenz is known to cause depression, we also performed 2 separate analyses of the association between virologic failure and depression in subgroups of patients treated with regimens containing efavirenz or nevirapine. Relative risk (RR) 11 signified an increased chance of virologic failure. Comparisons were made by Fisher's exact test for categorical data and Mann-Whitney U test or Student's t test for quantitative variables, as appropriate.
To investigate virologic failure as a time-dependent variable, we first constructed Kaplan-Meier curves according to the factors associated with virological failure (data not shown). The date of the baseline evaluation was considered the date of inclusion in the cohort. The date of the first of 2 consecutive virologic rebounds (defined as an HIV virus load of 1400 copies/mL) experienced by a patient while receiving an NNRTI regimen was considered to be the date of virologic failure. Patients were right-censored at the time of the last visit at which their virus load was determined to be controlled or at the time at which their NNRTI regimen was changed. Patients who underwent structured therapeutic interruption, defined as stopping all therapeutic regimens once for several months, in accordance with the health care provider (i.e., patients with long-term control of virus loads and high numbers of CD4 cells) were not considered to have experienced virologic failure but were right-censored at the time of the last virus load of !400 copies/mL. Strata were compared by the use of the logrank test. The proportional-hazard model was used to assess the independent effects of each factor found to be associated with virologic failure in univariate analysis. Time to the occurrence of NNRTI resistance was also constructed by the use of Kaplan-Meier curves according to factors associated with virologic failure. In case of missing data, patients were rightcensored at the time of the last virus load of !400 copies/mL. Data were analyzed by SAS software, version 8e (SAS Institute). All tests were 2-tailed.
was considered statistically P ! .05 significant.
RESULTS

Study population. During the baseline evaluation (August 1999-August 2000)
, 71 consecutive HIV-infected outpatients were selected. Their median age was 40 years (range, 23-69 years), and 56 patients (79%) were men (table 1). The most common risk factors for HIV infection were being a man who has sex with men (34%) and heterosexual activity (32%). The mean known duration of HIV seropositivity was 96.8 months; 28% of patients experienced AIDS. All but 9 patients had received previous therapy with antiretroviral drugs (PIs). The median duration of virological evaluation under NNRTI-based therapy was 29 months.
Virologic failure with NNRTIs. Virologic outcome according to baseline patient characteristics is shown in table 2. Virologic failure was significantly associated with previous nonadherence behaviors (RR, 1.7; 95% CI, 1.1-2.5;
), re-P p .034 peated drug holidays (RR, 4.4; 95% CI, 2.0-9.5; ), P p .0001 and younger age ( ). A trend was found for depression P p .021 in efavirenz subgroup (RR, 2.1; 95% CI, 0.9-3.9;
), but P p .13 no significant interaction was found in the relation between depression and virologic failure and whether a patient received efavirenz or nevirapine. Thus, each drug subgroup was merged for the subsequent analysis. Social support, medication knowledge, risk factor for HIV, sex, CD4 cell count, NNRTI choice, and other antiretroviral drugs prescribed were not significantly associated with viral outcome.
In the multivariate time-to-event Cox model ( Resistance with NNRTIs. Among the 20 patients who experienced virologic failure while receiving NNRTI-based regimens, 15 patients had their genotypes assessed at the time of virologic failure. In 9 (60%) of 15 patients, major resistance mutation (K103N in 7 patients, with additional codons for NNRTI resistance in 5 patients; K101E plus G190A/S in 2 patients) conferring cross-resistance to the NNRTI class was observed. Among the remaining patients without NNRTI resis- Figure 1 . Kaplan-Meier estimates of time to genotypic resistance for patients receiving a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, according to previous number of drug holidays at baseline. A drug holiday was defined as an unplanned interruption in treatment for у48 h). The rate of virologic failure with major NNRTI resistance was significantly higher in patients reporting several drug holidays ( by P ! .0001 the log-rank test).
tance, 3 of 6 had M184V/I conferring resistance to lamivudine, and 3 of 6 had wild-type failure.
As shown in figure 1 , reporting several previous drug holidays at baseline was significantly associated with the development of resistance to the NNRTI class, versus reporting р1 drug holiday at baseline (8 [ ). P ! .0001
DISCUSSION
In this study, standardized assessment of drug holidays was a strong and independent predictor of subsequent virologic failure in HIV-infected patients with initial virologic responses to NNRTI regimens. In addition, younger age and depression also independently predicted virologic failure. Genotypic mutations conferring cross-resistance to the NNRTI class were frequently associated with virologic failure. Drug holiday assessment at baseline predicted the development of resistance to the NNRTI class.
Adherence to therapy of у95% has been shown to be required to allow optimal antiretroviral efficacy of a PI-based regimen [6] . Although drug holidays and poor adherence were collinear (data not shown), they are not interchangeable concepts, because 95% adherence to therapy is compatible with multiple drug holidays. Consequently, data on the average percentage of adherence alone may not be enough to assess the risk of virologic failure and resistance in patients receiving NNRTI-based regimens and should be supplemented by a more qualitative evaluation. For example, what accounted for the missing percentage of therapy during the period of assessment? Were multiple single doses missed, were there several noncontiguous drug holidays, or was there a single continuous period of interruption of therapy? Our data and the data of others [16] suggest that experiencing several treatment interruptions results in a greater risk of developing NNRTI resistance than does missing multiple single doses or experiencing a single long interruption in therapy, because of the danger of NNRTI monotherapy [17] . The long half-life of NNRTIs, as compared with that of NRTIs, may allow NNRTI monotherapy after simultaneous cessation of the regimen. Consequently, patients and clinicians should be aware of the importance of stopping NNRTI therapy 7 days before stopping NRTI therapy, when possible [18] .
We are aware of several limitations to our study. First, 5 of 20 genotypes were unavailable. Second, self-reporting by patients is known to overestimate adherence to therapy. However, patient reports of lower adherence to therapy are usually reliable, and underestimation of the number of patients with low adherence as a result of measurement bias would be conservative in our findings. In addition, it is likely that resistance to NNRTIs occurred at low levels of adherence. For this reason, self-reported measures, even if they overestimate adherence to therapy, may be able to detect associations with NNRTI resistance. The cross-sectional design of the adherence evaluation precludes any inference between failure to adhere to therapy at the time of virologic failure and experiencing virologic failure, because of the dynamics of adherence to therapy [19] . Prospective adherence assessment performed by electronic devices would have provided more definitive evidence. However, previous studies in this setting have demonstrated that adherence to therapy tends to decline with time [19] , so patients reporting several previous drug holidays at baseline were not likely to resume continuous therapy during the period of virologic evaluation. In this line, previously nonadherent patients are more at risk of subsequent failure to adhere to therapy [20] . Consequently, because all of the patients had initial responses to the NNRTI-based regimen, we hypothesized that virologic failure and resistance were more likely to be related to additional repeated drug holidays, rather than to nucleoside reverse transcriptase inhibitor resistance mutations already generated by previous drug holidays or by suboptimal antiretroviral concentrations as a result of the interindividual pharmacokinetic of drugs. Finally, because we chose to include all patients with undetectable virus loads who received NNRTI therapy, some of them also were receiving PIs. The convenience and simplicity of NNRTI-based regimens would be lost in these cases. If we exclude those patients from our analysis, however, it does not affect our conclusions (data not shown).
Depression and younger age also independently predicted virologic failure. These results must be interpreted in the light of previous research in the area of adherence to antiretroviral therapy. Younger age and depression were both associated with failure to maintain long-term adherence to therapy at month 20 of a PI-based antiretroviral regimen in 277 patients reporting good adherence at month 4 (respectively, and P p .08 P p ) [21] . In another study of PI-based antiretroviral therapy .002 [6] , younger age ( ) and psychiatric morbidity ( P p .01 P p ) were independently associated with lower levels of adher-.04 ence to therapy, but only a borderline nonsignificant association was found between the presence of depression and virologic outcome ( ). The greater impact of depression on viral P p .07 outcome in this study may result from neuropsychiatric side effects of the NNRTI class.
Simplification of HAART with NNRTI-based regimens has been proposed to optimize adherence to therapy, a pivotal issue in controlling HIV replication and preventing disease progression or death [22] . Reducing the pill burden or daily dose with an NNRTI-based combination certainly improves quality of life [23] and possibly improves adherence to HAART [24] . In a previous report of prolonged induction versus maintenance therapy [25] , however, incomplete control of virus loads with the simpler therapy was highly correlated with lower quality of life (r, Ϫ0.58;
). Consequently, the potential gain in P p .009 terms of quality of life and adherence to therapy should be balanced with the low genetic barrier of this drug class and the possible neuropsychologic toxicity, particularly among patients reporting previous repeated drug holidays or with predictors of subsequent failure to adhere to therapy, such as younger age or depression. In these cases, the chance of long-term control of virus loads is low and the prevalence of mutations conferring cross-resistance to NNRTI is high. Before initiating treatment with an NNRTI class of antiretroviral drugs, risk factors for low adherence should be carefully evaluated rather than expected by the prescriber [26] . Special attention should be paid to side effects and to prevention of a decline in adherence to therapy, even in patients with an early virologic response to an NNRTI-based regimen. In case of virologic failure, genotyping should be performed systematically, even after first-line therapy with NNRTI-based HAART, because virologic failure is not always associated with NNRTI resistance.
Finally, because patients with lower adherence to therapy were more likely to report risk behaviors for transmission of HIV [27] , the prescription of NNRTI-based therapy in cases of low adherence to therapy may have public health consequences in terms of the transmission of resistant strains. In such cases, PI-based regimens, when available, may have a lower resistance cost for the community.
